Literature DB >> 16151285

Acinetobacter infection is associated with acquired glucose intolerance in burn patients.

Dominic Furniss1, Sinclair Gore, Berge Azadian, Simon R Myers.   

Abstract

Infection with antibiotic-resistant Acinetobacter spp. is an increasing problem in critical care environments worldwide. Acinetobacter spp. are known to produce an insulin-cleaving protease. We hypothesized that infection with Acinetobacter spp. was associated with the acquisition of glucose intolerance in burn patients. Data were collected prospectively on all 473 patients admitted to the Burns Centre between January 2002 and March 2003. A total of 3.4% of patients acquired glucose intolerance during admission. Patients with Acinetobacter spp. infection were 9.8 times more likely to develop glucose intolerance than those without the infection (P < .0001). The association persisted after controlling for TBSA (P < .001). In patients with deep Acinetobacter spp. infection, 47% had glucose intolerance, compared with 12% in those with infection of the burn only (P = .03). In patients with pre-existing diabetes mellitus, 27% developed Acinetobacter spp. infection compared with only 8.5% of patients without diabetes (P = .04). This study demonstrates a clear association between Acinetobacter spp. infection and glucose intolerance in burns patients.

Entities:  

Mesh:

Year:  2005        PMID: 16151285     DOI: 10.1097/01.bcr.0000176882.69354.7e

Source DB:  PubMed          Journal:  J Burn Care Rehabil        ISSN: 0273-8481


  8 in total

Review 1.  Diabetes mellitus and burns. Part II-outcomes from burn injuries and future directions.

Authors:  Ioannis Goutos; Rebecca Spenser Nicholas; Atisha A Pandya; Sudip J Ghosh
Journal:  Int J Burns Trauma       Date:  2015-03-20

2.  Diabetic murine models for Acinetobacter baumannii infection.

Authors:  Guanpingsheng Luo; Brad Spellberg; Teclegiorgis Gebremariam; Michael Bolaris; Hongkyu Lee; Yue Fu; Samuel W French; Ashraf S Ibrahim
Journal:  J Antimicrob Chemother       Date:  2012-03-02       Impact factor: 5.790

3.  Validation of a novel murine wound model of Acinetobacter baumannii infection.

Authors:  Mitchell G Thompson; Chad C Black; Rebecca L Pavlicek; Cary L Honnold; Matthew C Wise; Yonas A Alamneh; Jay K Moon; Jennifer L Kessler; Yuanzheng Si; Robert Williams; Suleyman Yildirim; Benjamin C Kirkup; Romanza K Green; Eric R Hall; Thomas J Palys; Daniel V Zurawski
Journal:  Antimicrob Agents Chemother       Date:  2013-12-16       Impact factor: 5.191

4.  Active and passive immunization protects against lethal, extreme drug resistant-Acinetobacter baumannii infection.

Authors:  Guanpingshen Luo; Lin Lin; Ashraf S Ibrahim; Beverlie Baquir; Paul Pantapalangkoor; Robert A Bonomo; Yohei Doi; Mark D Adams; Thomas A Russo; Brad Spellberg
Journal:  PLoS One       Date:  2012-01-10       Impact factor: 3.240

5.  Diabetes Exacerbates Infection via Hyperinflammation by Signaling through TLR4 and RAGE.

Authors:  Travis B Nielsen; Paul Pantapalangkoor; Jun Yan; Brian M Luna; Ken Dekitani; Kevin Bruhn; Brandon Tan; Justin Junus; Robert A Bonomo; Ann Marie Schmidt; Michael Everson; Frederick Duncanson; Terence M Doherty; Lin Lin; Brad Spellberg
Journal:  mBio       Date:  2017-08-22       Impact factor: 7.867

6.  Small protein A and phospholipase D immunization serves a protective role in a mouse pneumonia model of Acinetobacter baumannii infection.

Authors:  Haitao Li; Hongyi Tan; Yongbin Hu; Pinhua Pan; Xiaoli Su; Chengpin Hu
Journal:  Mol Med Rep       Date:  2017-06-06       Impact factor: 2.952

7.  Obesity and Type 2 Diabetes mellitus induce lipopolysaccharide tolerance in rat neutrophils.

Authors:  Wilson Mitsuo Tatagiba Kuwabara; Caroline Naomi Fukusawa Yokota; Rui Curi; Tatiana Carolina Alba-Loureiro
Journal:  Sci Rep       Date:  2018-12-03       Impact factor: 4.379

8.  Impaired host response and the presence of Acinetobacter baumannii in the serum microbiome of type-II diabetic patients.

Authors:  Dasith Perera; Sarah E Kleinstein; Benjamin Hanson; Hatice Hasturk; Ryan Eveloff; Marcelo Freire; Matthew Ramsey
Journal:  iScience       Date:  2020-12-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.